Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline NEWS PROVIDED BY Alphyn Biologics Dec 12, 2025, 07:30 ET Financing funds the global Phase 2b clinical trial in atopic dermatitis and Phase 2 clinical program in molluscum contagiosum ANNAPOLIS, Md., Dec. 12, 2025 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing…
Alphyn Expands Patent Estate with New U.S. Patent for Atopic Dermatitis Therapeutic NEWS PROVIDED BY Alphyn Biologics Oct 27, 2025, 07:30 ET Patent covers active pharmaceutical ingredient with protection until 2041 ANNAPOLIS, Md., Oct. 27, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and Trademark Office…
Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis Highlighted in Leading Peer-Reviewed Journal NEWS PROVIDED BY Alphyn Biologics Jul 01, 2025, 07:30 ET Expert dermatologist panel creates new atopic dermatitis (AD) algorithm (stepped diagnosis and treatment recommendations) emphasizing need for therapeutics that address AD’s intense itch, inflammation, and the AD disease stages of Staphylococcus aureus (Staph) colonization…
Alphyn Announces First Patient Dosed in CLEAR-AD1 Global Phase 2b Clinical Trial Program of Zabalafin Hydrogel for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Apr 08, 2025, 07:30 ET First topical therapeutic to directly treat the immuno-inflammatory and bacterial causes of the disease at all stages, from AD onset through infection ANNAPOLIS, Md., April 8,…
Alphyn Poster at American Academy of Dermatology Annual Meeting Highlights Potential of Zabalafin Hydrogel as Singular, Comprehensive Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 10, 2025, 07:30 ET Phase 2a clinical program demonstrates safety and efficacy for all endpoints in AD with and without secondary infection ANNAPOLIS, Md. and ORLANDO, Fla., March 10, 2025 /PRNewswire/ — Alphyn,…